Disseminated mucormycosis in a patient with severe COVID-19 on venovenous extracorporeal membrane oxygenation: A case report.
COVID-19 associated mucormycosis
Invasive fungal infection
Invasive mucormycosis
Steroid
Journal
IDCases
ISSN: 2214-2509
Titre abrégé: IDCases
Pays: Netherlands
ID NLM: 101634540
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
03
2022
revised:
18
07
2022
accepted:
18
07
2022
pubmed:
26
7
2022
medline:
26
7
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Since the global outbreak of coronavirus disease 2019 (COVID-19), there have been several reports of mucormycosis as a secondary complication. However, the disseminated type of mucormycosis is extremely rare. A 58-year-old male patient with COVID-19 started receiving venovenous extracorporeal membrane oxygenation because of severe respiratory failure. During hospitalization, intra-abdominal hemorrhage occurred and an emergency laparotomy was performed. Subsequently, the patient suffered septic shock, and part of the small intestines and the abdominal wall became necrotic. Finally, the patient died. At autopsy, he was diagnosed with disseminated mucormycosis. Disseminated mucormycosis should be considered in patients with COVID-19 with refractory sepsis unresponsive to broad-spectrum antimicrobial therapy.
Sections du résumé
Background
UNASSIGNED
Since the global outbreak of coronavirus disease 2019 (COVID-19), there have been several reports of mucormycosis as a secondary complication. However, the disseminated type of mucormycosis is extremely rare.
Case
UNASSIGNED
A 58-year-old male patient with COVID-19 started receiving venovenous extracorporeal membrane oxygenation because of severe respiratory failure. During hospitalization, intra-abdominal hemorrhage occurred and an emergency laparotomy was performed. Subsequently, the patient suffered septic shock, and part of the small intestines and the abdominal wall became necrotic. Finally, the patient died. At autopsy, he was diagnosed with disseminated mucormycosis.
Conclusion
UNASSIGNED
Disseminated mucormycosis should be considered in patients with COVID-19 with refractory sepsis unresponsive to broad-spectrum antimicrobial therapy.
Identifiants
pubmed: 35874315
doi: 10.1016/j.idcr.2022.e01578
pii: S2214-2509(22)00206-2
pmc: PMC9295314
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01578Informations de copyright
© 2022 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare.